Valuation Amgen Inc. Xetra

Stocks

Real-time Estimate Tradegate 01:30:07 01/10/26 am AEST			5-day change	1st Jan Change
373.65 ^EUR	+1.58%		+4.75%	+33.43%

12:46am	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
29/09	Scotiabank Raises Amgen Price Target to $500 From $450, Sector Outperform Rating Kept	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	126,718	140,139	154,142	140,103	176,250	229,033	-	-
Change	-	10.59%	9.99%	-9.11%	25.8%	29.95%	-	-
Enterprise Value (EV) ¹	151,990	169,779	207,811	188,229	221,725	270,519	264,850	259,847
Change	-	11.7%	22.4%	-9.42%	17.8%	22.01%	-2.1%	-1.89%
P/E	21.9x	21.7x	23.1x	34.5x	23x	26.8x	24x	23x
PBR	18.7x	38.3x	24.7x	23.8x	20.4x	20.2x	16.5x	13.3x
PEG	-	1.2x	7.36x	-0.9x	0.3x	2.4x	2.1x	5.54x
Capitalization / Revenue	4.88x	5.32x	5.47x	4.19x	4.8x	5.88x	5.68x	5.5x
EV / Revenue	5.85x	6.45x	7.37x	5.63x	6.03x	6.95x	6.57x	6.24x
EV / EBITDA	9.61x	10.5x	11.9x	9.13x	10.4x	12.4x	11.9x	11.6x
EV / EBIT	12.2x	13.3x	15.5x	12.5x	13.7x	15.9x	15x	14.1x
EV / FCF	18.1x	19.3x	28.2x	18.1x	27.4x	24.3x	18x	16.9x
FCF Yield	5.51%	5.17%	3.54%	5.52%	3.65%	4.11%	5.56%	5.92%
Dividend per Share ²	7.04	7.76	8.52	9	9.52	10.09	10.66	11.12
Rate of return	3.13%	2.95%	2.96%	3.45%	2.91%	2.38%	2.52%	2.63%
EPS ²	10.28	12.11	12.49	7.56	14.23	15.83	17.67	18.41
Distribution rate	68.5%	64.1%	68.2%	119%	66.9%	63.7%	60.3%	60.4%
Net sales ¹	25,979	26,323	28,190	33,424	36,751	38,938	40,309	41,654
EBITDA ¹	15,822	16,178	17,470	20,620	21,370	21,864	22,213	22,322
EBIT ¹	12,424	12,761	13,399	15,028	16,203	16,964	17,686	18,396
Net income ¹	5,893	6,552	6,717	4,090	7,711	8,581	9,393	9,971
Net Debt ¹	25,272	29,640	53,669	48,126	45,475	41,485	35,817	30,814
Reference price ²	224.97	262.64	288.02	260.64	327.31	423.64	423.64	423.64
Nbr of stocks (in thousands)	563,266	533,579	535,178	537,533	538,481	540,632	-	-
Announcement Date	7/2/22	31/1/23	6/2/24	4/2/25	3/2/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
ELI LILLY AND COMPANY	33.68x	12.2x	24.79x	0.59%	1,056B
JOHNSON & JOHNSON	29.76x	6.61x	18.5x	2%	645B
ABBVIE INC.	33.32x	7.79x	16.11x	2.63%	465B
MERCK & CO., INC.	108.6x	6.05x	25.67x	2.29%	368B
ROCHE HOLDING AG	19.01x	4.64x	11.49x	2.87%	335B
NOVARTIS AG	20.51x	5.32x	13.17x	3.01%	275B
ASTRAZENECA PLC	20.92x	4.34x	12.36x	2.04%	255B
AMGEN INC.	26.76x	6.95x	12.37x	2.38%	229B
GILEAD SCIENCES, INC.	-45.76x	6.66x	26x	2.18%	188B
Average	27.42x	6.73x	17.83x	2.22%	423.98B
Weighted average by Cap.	32.80x	7.85x	19.23x	1.9%